|Awarded On||August 18, 2021|
|Title||Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Institution/Organization||Marker Therapeutics, Inc.|
|Principal Investigator/Program Director||Juan Vera|
*Pending contract negotiation
Marker Therapeutics, a Texas-based company, focuses on novel cell-based therapies for a variety of cancer indications. Marker proposes MT-401 for the treatment of acute myeloid leukemia (AML), supporting CPRIT’s mission for novel cancer treatments. AML is a deadly cancer, treated with chemotherapy, often followed by stem cell transplant (SCT). However, relapse after SCT remains a major cause of death, with poor 1-year survival. Limited treatments are available for patients who fail chemotherapy and SCT. MT-401 is a novel T cell-based therapy that targets multiple tumor-associated antigens (mTAAs) highly expressed in AML cancer cells (with absent / low expression in healthy tissue), minimizin...